PyInvesting

Market research

MBG.F Marinomed Biotech AG

F EUR Consumer Cyclical

Latest close

Loading market data…

Test a moving-average rule with historical data.

Market cap
43B
P/E ratio
8.52
Analyst target
57.1546
Dividend yield
7.7%
Beta
0.68

Community

Investor discussion

1 comment

Admin profile picture
Admin

5 years, 5 months ago

Marinomed Biotech AG is currently in a long term downtrend where the price is trading 0.7% below its 200 day moving average.

From a valuation standpoint, the stock is 98.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 25.8.

Marinomed Biotech AG's total revenue rose by 67.7% to $3M since the same quarter in the previous year.

Its net income has dropped by 24.7% to $-2M since the same quarter in the previous year.

Finally, its free cash flow fell by 351.3% to $-3M since the same quarter in the previous year.

Based on the above factors, Marinomed Biotech AG gets an overall score of 2/5.